Elesclomol is an anticancer drug that targets mitochondrial metabolism. In the past,
elesclomol was recognized as an inducer of oxidative stress, but now it has also been found …

Simple Summary Cutaneous melanoma represents the most aggressive form of skin cancer
and its occurrence, development, and progression are based on the accumulation of several …

Melanoma is considered one of the most aggressive skin cancers. It spreads and
metastasizes quickly and is intrinsically resistant to most conventional chemotherapeutics …

The EGFR family play a significant role in cell signal transduction and their overexpression
is implicated in the pathogenesis of numerous human solid cancers. Inhibition of the EGFR …

Due to genetic changes in DNA (deoxyribonucleic acid) sequences, cancer continues to be
the second most prevalent cause of death. The traditional target-directed approach, which is …

Melanoma is the deadliest form of skin cancer and considered intrinsically resistant to
chemotherapy. Nearly all melanomas harbor mutations that activate the RAS/mitogen …

Therapies that target oncogenes and immune checkpoint molecules constitute a major
group of treatments for metastatic melanoma. A mutation in BRAF (BRAF V600E) affects …

Constitutively active mutated BRAF kinase occurs in more than 40% of patients suffering
from melanoma. To block its activity, a specific inhibitor, vemurafenib, is applied as a …

Purpose: The limited knowledge on the molecular profile of patients with BRAF-mutant non–
small cell lung cancer (NSCLC) who progress under BRAF-targeted therapies (BRAF-TT) …

Immune checkpoint blockade and MAPK-targeted combined therapy is a promising regimen
for advanced melanoma patients. However, the clinical benefit from this combo regimen …